ClinicalThought Commentary


Share

Program Content

Activities

  • Adj Immunotherapy for High-Risk HCC
    Incorporating Adjuvant Immunotherapy Into the Treatment of Patients With High-Risk HCC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 08, 2024

    Expires: April 07, 2025

Faculty

cover img faculity

Amit Singal, MD, MS

Professor of Medicine
Medical Director of Liver Tumor Program
Chief of Hepatology
UT Southwestern Medical Center
Dallas, Texas

cover img faculity

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Provided by

ProCE Banner

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group.

Genentech, a member of the Roche Group